Researchers Identify Lysosomal "Drug Reservoirs" as Key Factor in Inconsistent Cancer Treatment Efficacy

Scientists discover that lysosomes act as "drug reservoirs," trapping cancer medication and causing uneven treatment distribution within tumors.

By: AXL Media

Published: Mar 27, 2026, 11:58 AM EDT

Source: Information for this report was sourced from ScienceDaily and the Medical Research Council (MRC) Laboratory of Medical Sciences.

Decoding the Heterogeneity of Cancer Drug Response

The clinical challenge of why identical cancer therapies yield vastly different results across patient populations has long stymied oncologists. New research published in Nature Communications, led by Dr. Louise Fets at the MRC Laboratory of Medical Sciences (LMS), suggests the answer may lie in the internal "recycling centers" of tumor cells. By tracking the movement of PARP inhibitors through ovarian tumor samples, scientists discovered that drugs do not distribute evenly. Instead, they often accumulate in high concentrations in certain areas—termed "hotspots"—while leaving other regions of the same tumor virtually untreated.

The Role of Lysosomes as Intracellular Storage Units

The study identified lysosomes—organelles responsible for breaking down cellular waste—as the primary drivers of this uneven distribution. Certain drugs, specifically rucaparib and niraparib, are drawn into these compartments where they become trapped. These lysosomes then act as slow-release reservoirs, holding the medication and releasing it gradually over time. While this increases long-term exposure for some cells, it simultaneously starves others of the necessary dosage to trigger cell death. This "trapping" mechanism was notably absent in other PARP inhibitors like olaparib, indicating that drug structure plays a vital role in how these reservoirs form.

Advancing Precision Medicine via Multimodal Imaging

To visualize this phenomenon, the research team employed a sophisticated combination of mass spectrometry imaging and spatial transcriptomics. Using "explants"—slices of human ovarian tumors kept alive in a laboratory setting—the team produced high-resolution maps of drug uptake. This allowed them to compare gene activity in high-drug regions against low-drug regions within the same tissue slice. Dr. Zoe Hall, Associate Professor at Imperial College London, noted that this spatial mapping allows researchers to pinpoint exactly where treatments fail at a molecular level, offering a "molecular signature" that could eventually help doctors tailor therapies to a patient's specific tumor profile.